169 related articles for article (PubMed ID: 12053862)
1. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
Hollywood E
Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
[TBL] [Abstract][Full Text] [Related]
2. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Needle MN
Semin Oncol; 2002 Oct; 29(5 Suppl 14):55-60. PubMed ID: 12422314
[TBL] [Abstract][Full Text] [Related]
3. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
Herbst RS; Kim ES; Harari PM
Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
5. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab: adverse event profile and recommendations for toxicity management.
Thomas M
Clin J Oncol Nurs; 2005 Jun; 9(3):332-8. PubMed ID: 15973844
[TBL] [Abstract][Full Text] [Related]
7. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
[No Abstract] [Full Text] [Related]
8. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
Busam KJ; Capodieci P; Motzer R; Kiehn T; Phelan D; Halpern AC
Br J Dermatol; 2001 Jun; 144(6):1169-76. PubMed ID: 11422037
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor biology (IMC-C225).
Kim ES; Khuri FR; Herbst RS
Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
[TBL] [Abstract][Full Text] [Related]
11. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients.
Bossi P; Liberatoscioli C; Bergamini C; Locati LD; Fava S; Rinaldi G; Orlandi E; Olmi P; Tagliabue E; Ménard S; Licitra L
Ann Oncol; 2007 Mar; 18(3):601-2. PubMed ID: 17074970
[No Abstract] [Full Text] [Related]
12. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X; Lacouture ME; Jia Y; Wu S
Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.
Motzer RJ; Amato R; Todd M; Hwu WJ; Cohen R; Baselga J; Muss H; Cooper M; Yu R; Ginsberg MS; Needle M
Invest New Drugs; 2003 Feb; 21(1):99-101. PubMed ID: 12795534
[TBL] [Abstract][Full Text] [Related]
14. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
Ouwerkerk J; Boers-Doets C
Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
[TBL] [Abstract][Full Text] [Related]
15. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.
Pinto C; Barone CA; Girolomoni G; Russi EG; Merlano MC; Ferrari D; Maiello E; ;
Oncologist; 2011; 16(2):228-38. PubMed ID: 21273511
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
17. Manage infusion reactions from cetuximab.
Becze E
ONS Connect; 2008 Sep; 23(9):18-9. PubMed ID: 18807709
[No Abstract] [Full Text] [Related]
18. Images in clinical medicine. Cetuximab-associated acneiform eruption.
Moss JE; Burtness B
N Engl J Med; 2005 Nov; 353(19):e17. PubMed ID: 16282170
[No Abstract] [Full Text] [Related]
19. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
Jatoi A; Green EM; Rowland KM; Sargent DJ; Alberts SR
Oncology; 2009; 77(2):120-3. PubMed ID: 19622902
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]